SCHEMBL4912839

SCHEMBL4912839

C[C@H](Oc1ccc(Cl)cc1)C(=O)Nc1ccccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.66
TDP1 Q9NUW8 2/20 0.66
KDM4E B2RXH2 1/20 0.64
HTT P42858 1/20 0.64
ALDH1A1 P00352 1/20 0.60
MAPK1 P28482 1/20 0.60
HPGD P15428 1/20 0.59
CRHBP P24387 1/20 0.58
CRHR2 Q13324 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
TRPM4 Q8TD43 1/20 0.55
GAA P10253 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
ADORA2A P29274 1/20 0.54
ADORA1 P30542 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
LMNA P02545 1/20 0.51
TRPA1 O75762 1/20 0.49
DHODH Q02127 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065560 0.88 TSHR (0.67) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL4917385 0.87 TSHR (0.66) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL11214634 0.85 CRHBP (0.62) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL10175696 0.82 KMT2A (0.63) TSHRHTTALDH1A1HPGDCRHBP
SCHEMBL2610075 0.79 KMT2A (0.72) TSHRHTTHPGDMEN1KMT2A
SCHEMBL2610073 0.79 KMT2A (0.72) TSHRHTTHPGDMEN1KMT2A
SCHEMBL10175988 0.79 KMT2A (0.72) TSHRHTTHPGDMEN1KMT2A
SCHEMBL4916080 0.79 TSHR (0.67) TSHRTDP1KDM4EHTTALDH1A1
SCHEMBL2610084 0.77 PORCN (0.63) TSHRALDH1A1HPGDCRHBPCRHR2
SCHEMBL2610080 0.77 KMT2A (0.65) TSHRHTTALDH1A1HPGDCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US claimed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US claimed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US claimed
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2008-10-30 US disclosed
US-7408078-B2 Anthranilic acid derivatives useful in treating infection with hepatitis C virus WYETH (US) 2008-08-05 US disclosed
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus VIROPHARMA INCORPORATED 2005-01-06 US disclosed
WO-2004091724-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004192-A1 Anthranilic acid derivatives useful in treating infection with hepatitis C virus HCCS, ALAD, HAVCR2 TSHR 4195/4885TDP1 4850/4885KDM4E 2214/4885
US-20080269333-A1 ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS HCCS, ALAD, HAVCR2 TSHR 4195/4885TDP1 4850/4885KDM4E 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.